Beijing Centergate Technologies (000931.SZ): Registration application for Non-Pravastatin tablets has been accepted.

Beijing Centergate Technologies(000931.SZ) announced that its subsidiary company, Duoduo Pharmaceutical Co., Ltd. (referred to as Duoduo Pharma), recently received a "Notice of Acceptance" issued by the National Medical Products Administration for the registration application of Febuxostat tablets (specifications: 20mg, 40mg). The indication for this application is for the long-term treatment of hyperuricemia in gout patients, and it is not recommended for hyperuricemia without clinical symptoms.